PTK2 and non-small cell lung carcinoma: This broad efficacy is also supported by the co-upregulation of FAK and c-Myc in nearly a quarter of the NSCLC adenocarcinomas and at mRNA level in our NSCLC patient cohort (Figures 6, 7).